These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7648764)

  • 1. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status.
    Yasuda S; Horai Y; Tomono Y; Nakai H; Yamato C; Manabe K; Kobayashi K; Chiba K; Ishizaki T
    Clin Pharmacol Ther; 1995 Aug; 58(2):143-54. PubMed ID: 7648764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation.
    Ishizaki T; Chiba K; Manabe K; Koyama E; Hayashi M; Yasuda S; Horai Y; Tomono Y; Yamato C; Toyoki T
    Clin Pharmacol Ther; 1995 Aug; 58(2):155-64. PubMed ID: 7648765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype.
    Tanaka M; Ohkubo T; Otani K; Suzuki A; Kaneko S; Sugawara K; Ryokawa Y; Hakusui H; Yamamori S; Ishizaki T
    Clin Pharmacol Ther; 1997 Dec; 62(6):619-28. PubMed ID: 9433390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin.
    Tanaka M; Ohkubo T; Otani K; Suzuki A; Kaneko S; Sugawara K; Ryokawa Y; Ishizaki T
    Clin Pharmacol Ther; 2001 Mar; 69(3):108-13. PubMed ID: 11240974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status.
    Sohn DR; Kwon JT; Kim HK; Ishizaki T
    Clin Pharmacol Ther; 1997 May; 61(5):574-82. PubMed ID: 9164419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers.
    Yasuda S; Ohnishi A; Ogawa T; Tomono Y; Hasegawa J; Nakai H; Shimamura Y; Morishita N
    Int J Clin Pharmacol Ther; 1994 Sep; 32(9):466-73. PubMed ID: 7820329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population.
    Sohn DR; Kobayashi K; Chiba K; Lee KH; Shin SG; Ishizaki T
    J Pharmacol Exp Ther; 1992 Sep; 262(3):1195-202. PubMed ID: 1527724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study.
    Balian JD; Sukhova N; Harris JW; Hewett J; Pickle L; Goldstein JA; Woosley RL; Flockhart DA
    Clin Pharmacol Ther; 1995 Jun; 57(6):662-9. PubMed ID: 7781266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin.
    Böttiger Y; Tybring G; Götharson E; Bertilsson L
    Clin Pharmacol Ther; 1997 Oct; 62(4):384-91. PubMed ID: 9357389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin.
    Sarich T; Kalhorn T; Magee S; al-Sayegh F; Adams S; Slattery J; Goldstein J; Nelson S; Wright J
    Clin Pharmacol Ther; 1997 Jul; 62(1):21-8. PubMed ID: 9246016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans.
    Partovian C; Jacqz-Aigrain E; Keundjian A; Jaillon P; Funck-Brentano C
    Clin Pharmacol Ther; 1995 Sep; 58(3):257-63. PubMed ID: 7554698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
    Andersson T; Holmberg J; Röhss K; Walan A
    Br J Clin Pharmacol; 1998 Apr; 45(4):369-75. PubMed ID: 9578184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects.
    Tybring G; Böttiger Y; Widén J; Bertilsson L
    Clin Pharmacol Ther; 1997 Aug; 62(2):129-37. PubMed ID: 9284848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin.
    Rost KL; Brösicke H; Brockmöller J; Scheffler M; Helge H; Roots I
    Clin Pharmacol Ther; 1992 Aug; 52(2):170-80. PubMed ID: 1505152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment.
    Rost KL; Brockmöller J; Esdorn F; Roots I
    J Hepatol; 1995 Sep; 23(3):268-77. PubMed ID: 8550990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of inhibition of H+, K(+)-ATPase by sodium 2-[[4-(3- methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole (E3810).
    Nochi S; Yokoyama Y; Narukawa M; Ebine K; Murahashi M; Kawakami Y; Asakawa N; Sato T
    Chem Pharm Bull (Tokyo); 1996 Mar; 44(3):552-8. PubMed ID: 8882453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor in extensive and poor metabolizers of pantoprazole--a preliminary study.
    Tanaka M; Yamazaki H; Hakusui H; Nakamichi N; Sekino H
    Chirality; 1997; 9(1):17-21. PubMed ID: 9094198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of a new H(+)-K+ ATPase inhibitor (E3810) and its four metabolites in human plasma by high-performance liquid chromatography.
    Nakai H; Shimamura Y; Kanazawa T; Yasuda S; Kayano M
    J Chromatogr B Biomed Appl; 1994 Oct; 660(1):211-20. PubMed ID: 7858718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione.
    Fujisaki H; Shibata H; Oketani K; Murakami M; Fujimoto M; Wakabayashi T; Yamatsu I; Yamaguchi M; Sakai H; Takeguchi N
    Biochem Pharmacol; 1991 Jul; 42(2):321-8. PubMed ID: 1650210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in pharmacokinetics of omeprazole and its metabolites by gender and CYP2C19 genotype in Pakistani male and female subjects.
    Nazir S; Iqbal Z; Ahmad L; Ahmad S
    Pak J Pharm Sci; 2016 May; 29(3):887-94. PubMed ID: 27166533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.